JUDGMENT :

JAYANT NATH, J.

IA No.1803/2019 in CS(COMM) 62/2019

IA No.9072/2020 in CS(COMM) 425/2020

IA No.12284/2020 in CS(COMM) 557/2020 and

1. The issue in the aforenoted four suits are largely common and pertains to the plea of the plaintiffs’ of alleged infringement of the Indian Patent IN 229051 of plaintiff No.1.

IA No.4728/2021 in CS(COMM) 156/2021

2. For the purpose of present judgment, I will deal with the facts of the first suit, namely, IA No. 1803/2019 in CS(COMM) 62/2019, titled ‘Novartis AG & Ors. v. NATCO Pharma Limited’.

3. This is an application filed on behalf of the plaintiffs under Order 39 Rules 1 and 2 CPC seeking an ex parte injunction to restrain the defendant, its agents, etc. from manufacturing, importing, selling, offering for sale, etc. any pharmaceutical composition comprising a combination of Valsartan or a pharmaceutically acceptable salt thereof and Sacubitril or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier or more specifically a pharmaceutical composition comprising combination of Sacubitril +Valsartan as a sodium salt complex or in any other form which may amount to infringement of Indian Patent No.229051 of plaintiff No.1.

4